Abstract
37 Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals or no treatment in England: A retrospective cohort study
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have